What is ParaPRO?
ParaPRO specializes in creating advanced treatments for infestations that impact public health, with a particular emphasis on conditions like head lice and scabies. Their flagship product, Natroba, is a topical suspension recognized for its efficacy in treating head lice and is a frequently prescribed solution within its market segment. The company's mission is to enhance the well-being of families and support pediatric and family practices through the provision of effective parasitic infection solutions. By leveraging spinosad, a naturally derived and highly effective anti-parasitic agent, ParaPRO is positioned as a key player in addressing treatment resistance.
How much funding has ParaPRO raised?
ParaPRO has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in ParaPRO
PPP
Public-Private Partnership
What's next for ParaPRO?
With the recent major strategic investment and its established position in the late-stage funding landscape, ParaPRO is poised for significant expansion. The company's focus on addressing persistent public health concerns, particularly in the pediatric and family health sectors, provides a strong foundation for future growth. Continued development and market penetration of its innovative therapies, such as Natroba, are anticipated. The strategic backing suggests a focus on scaling operations, potentially expanding its product pipeline, and further solidifying its market leadership in parasitic infection treatments.
See full ParaPRO company page
